Medical Oncology Group of Australia position statement: COVID‐19 vaccination in patients with solid tumours

Field	Value	Language
dc.contributor.author	Kanjanapan, Yada	en
dc.contributor.author	Blinman, Prunella	en
dc.contributor.author	Underhill, Craig	en
dc.contributor.author	Karikios, Deme	en
dc.contributor.author	Segelov, Eva	en
dc.contributor.author	Yip, Desmond	en
dc.date.accessioned	2021-07-06T23:34:20Z
dc.date.available	2021-07-06T23:34:20Z
dc.date.issued	2021
dc.identifier.uri	https://hdl.handle.net/2123/25591
dc.description.abstract	People with cancer are vulnerable to increased morbidity and mortality from the coronavirus disease 2019 (COVID-19). COVID-19 vaccination is key to protecting the population of people with cancer from adverse outcomes of SARS-CoV-2 infection. The Medical Oncology Group of Australia aimed to address the considerations around COVID-19 vaccination in people with cancer, in particular, safety and efficacy of vaccination. The assessment of patients with generalised allergic reaction to anti-cancer therapy containing vaccine components and practical implementation of vaccination of people on active anti-cancer therapy are also discussed.	en
dc.language.iso	en	en
dc.rights	Other
dc.subject	COVID-19	en
dc.subject	Coronavirus	en
dc.title	Medical Oncology Group of Australia position statement: COVID‐19 vaccination in patients with solid tumours	en
dc.type	Article	en
dc.identifier.doi	10.1111/imj.15339
usyd.faculty	Faculty of Medicine and Health, Sydney Medical School	en

Associated file/s

There are no files associated with this item.